Phathom Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Phathom Pharmaceuticals (PHAT).

Price Target Range — 11 Quarters

Analyst Consensus — 8 Analysts

6Buy

2Hold

Consensus RatingBuy# Analysts8Avg. Consensus PT$18Upside to Avg. PT+139.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 9, 2026	Leerink Partners	Daniel Clark	Initiate	Market Perform	$10
Aug 17, 2026	Barclays	Glen Santangelo	PT Cut	Overweight	$18→$14
Jul 31, 2026	Guggenheim	Yatin Suneja	PT Cut	Buy	$25→$22
Jul 31, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$26
Jul 30, 2026	Needham	Joseph Stringer	PT Cut	Buy	$28→$22
Jun 17, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$26
Mar 27, 2026	Barclays	Glen Santangelo	Upgrade	Equal-Weight→Overweight	$16→$18
Feb 27, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$20→$25
Dec 9, 2025	Barclays	Glen Santangelo	Initiate	Equal-Weight	$16
Oct 31, 2025	HC Wainwright & Co.	Matthew Caufield	PT Raise	Buy	$20→$26
Jun 9, 2025	Craig-Hallum	Chase Knickerbocker	PT Raise	Buy	$12→$17
Jun 9, 2025	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$20
Jun 6, 2025	Needham	Joseph Stringer	Maintained	Buy	$28
May 2, 2025	Craig-Hallum	Chase Knickerbocker	PT Cut	Buy	$19→$12
May 2, 2025	Goldman Sachs	Paul Choi	PT Cut	Neutral	$10→$5
May 2, 2025	Guggenheim	Yatin Suneja	PT Cut	Buy	$18→$12
May 2, 2025	HC Wainwright & Co.	Matthew Caufield	PT Cut	Buy	$28→$20
Apr 21, 2025	Needham	Joseph Stringer	Maintained	Buy	$28
Apr 17, 2025	Goldman Sachs	Paul Choi	PT Cut	Neutral	$12→$10
Apr 9, 2025	Needham	Joseph Stringer	Maintained	Buy	$28

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Leerink Partners Initiates Coverage On Phathom Pharmaceuticals with Market Perform Rating, Announces Price Target of $10

Leerink Partners analyst Daniel Clark initiates coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) with a Market Perform rating and announces Price Target of $10.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Phathom Pharmaceuticals, Lowers Price Target to $14

Barclays analyst Glen Santangelo maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Overweight and lowers the price target from $18 to $14.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

Guggenheim analyst Yatin Suneja maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $25 to $22.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.

Benzinga Newsdesk

PRO
Needham Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

Needham analyst Joseph Stringer maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $28 to $22.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.

Benzinga Newsdesk

Phathom Pharmaceuticals Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Phathom Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Leerink Partners Initiates Coverage On Phathom Pharmaceuticals with Market Perform Rating, Announces Price Target of $10

PRO
Barclays Maintains Overweight on Phathom Pharmaceuticals, Lowers Price Target to $14

PRO
Guggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

PRO
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

PRO
Needham Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

PRO
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

People Also Watch

People Also Watch

Phathom Pharmaceuticals Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Phathom Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLeerink Partners Initiates Coverage On Phathom Pharmaceuticals with Market Perform Rating, Announces Price Target of $10

PROBarclays Maintains Overweight on Phathom Pharmaceuticals, Lowers Price Target to $14

PROGuggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

PROHC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

PRONeedham Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

PROHC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

People Also Watch

People Also Watch

PRO
Leerink Partners Initiates Coverage On Phathom Pharmaceuticals with Market Perform Rating, Announces Price Target of $10

PRO
Barclays Maintains Overweight on Phathom Pharmaceuticals, Lowers Price Target to $14

PRO
Guggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

PRO
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

PRO
Needham Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

PRO
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target